Prestige Consumer Healthcare Key Executives
This section highlights Prestige Consumer Healthcare's key executives, including their titles and compensation details.
Find Contacts at Prestige Consumer Healthcare
(Showing 0 of )
Prestige Consumer Healthcare Earnings
This section highlights Prestige Consumer Healthcare's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2025 | 2025-02-06 | $1.16 | $1.22 |
| Read Transcript | Q2 | 2025 | 2024-11-09 | N/A | N/A |
| Read Transcript | Q1 | 2025 | 2024-08-08 | $0.86 | $0.90 |
| Read Transcript | Q4 | 2024 | 2024-05-15 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-02-08 | $1.04 | $1.06 |
| Read Transcript | Q2 | 2024 | 2023-11-02 | $1.07 | $1.07 |
| Read Transcript | Q1 | 2024 | 2023-08-05 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2023-05-06 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-02-02 | $1.01 | $1.04 |
| Read Transcript | Q2 | 2023 | 2022-11-06 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2022-08-07 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Prestige Consumer Healthcare, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.13B | $1.13B | $1.09B | $943.37M | $963.01M |
| Cost of Revenue | $500.91M | $502.43M | $466.17M | $395.89M | $410.79M |
| Gross Profit | $624.45M | $625.29M | $620.65M | $547.47M | $552.22M |
| Gross Profit Ratio | 55.49% | 55.45% | 57.11% | 58.03% | 57.34% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $106.15M | $107.35M | $108.52M | $85.54M | $89.11M |
| Selling and Marketing Expenses | $153.31M | $145.06M | $157.34M | $140.59M | $147.19M |
| Selling General and Administrative Expenses | $259.47M | $252.41M | $265.86M | $226.13M | $236.31M |
| Other Expenses | $22.55M | $25.08M | $24.87M | $23.94M | $24.76M |
| Operating Expenses | $282.02M | $277.49M | $290.73M | $250.07M | $261.07M |
| Cost and Expenses | $782.93M | $779.92M | $756.89M | $645.96M | $671.86M |
| Interest Income | $- | $69.16M | $64.29M | $82.33M | $342.00K |
| Interest Expense | $67.16M | $69.16M | $64.29M | $82.33M | $96.57M |
| Depreciation and Amortization | $30.68M | $38.94M | $38.80M | $37.25M | $37.78M |
| EBITDA | $373.86M | $14.19M | $351.61M | $310.38M | $325.50M |
| EBITDA Ratio | 33.22% | 1.26% | 32.35% | 32.90% | 33.80% |
| Operating Income | $342.43M | $345.47M | $329.92M | $297.40M | $291.15M |
| Operating Income Ratio | 30.43% | 30.63% | 30.36% | 31.53% | 30.23% |
| Total Other Income Expenses Net | $-66.40M | $-71.50M | $-67.46M | $-93.29M | $-100.00M |
| Income Before Tax | $276.02M | $-93.92M | $262.46M | $204.11M | $191.15M |
| Income Before Tax Ratio | 24.53% | -8.33% | 24.15% | 21.64% | 19.85% |
| Income Tax Expense | $66.69M | $-11.61M | $57.08M | $39.43M | $48.87M |
| Net Income | $209.34M | $-82.31M | $205.38M | $164.68M | $142.28M |
| Net Income Ratio | 18.60% | -7.30% | 18.90% | 17.46% | 14.77% |
| EPS | $4.21 | $-1.65 | $4.09 | $3.28 | $2.81 |
| EPS Diluted | $4.17 | $-1.65 | $4.04 | $3.25 | $2.78 |
| Weighted Average Shares Outstanding | 49.76M | 49.88M | 50.26M | 50.21M | 50.72M |
| Weighted Average Shares Outstanding Diluted | 50.18M | 49.89M | 50.84M | 50.60M | 51.14M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $290.32M | $283.55M | $267.14M | $276.99M | $282.74M | $286.32M | $279.31M | $285.87M | $275.52M | $289.27M | $277.06M | $266.94M | $274.47M | $276.23M | $269.18M | $237.76M | $238.79M | $237.42M | $229.39M | $251.24M |
| Cost of Revenue | $129.27M | $126.17M | $126.82M | $130.86M | $124.80M | $126.30M | $124.64M | $132.10M | $125.12M | $128.26M | $116.94M | $118.07M | $119.41M | $118.51M | $110.17M | $100.70M | $99.90M | $99.76M | $95.53M | $107.33M |
| Gross Profit | $161.05M | $157.38M | $140.32M | $146.13M | $157.94M | $160.02M | $154.67M | $153.76M | $150.40M | $161.01M | $160.12M | $148.86M | $155.06M | $157.71M | $159.01M | $137.06M | $138.89M | $137.66M | $133.87M | $143.91M |
| Gross Profit Ratio | 55.47% | 55.50% | 52.53% | 52.76% | 55.86% | 55.89% | 55.38% | 53.79% | 54.59% | 55.66% | 57.79% | 55.77% | 56.49% | 57.10% | 59.07% | 57.64% | 58.16% | 57.98% | 58.36% | 57.28% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $26.18M | $26.07M | $28.91M | $26.46M | $26.00M | $26.00M | $27.69M | $27.67M | $26.54M | $26.44M | $26.71M | $27.81M | $25.98M | $32.25M | $22.47M | $23.82M | $21.39M | $20.39M | $19.93M | $23.58M |
| Selling and Marketing Expenses | $37.95M | $41.41M | $39.37M | $37.52M | $39.47M | $40.10M | $36.23M | $30.87M | $30.42M | $43.82M | $39.95M | $36.94M | $40.24M | $40.73M | $39.44M | $36.42M | $38.08M | $38.34M | $27.75M | $40.17M |
| Selling General and Administrative Expenses | $64.13M | $67.48M | $68.28M | $63.98M | $65.47M | $66.10M | $63.92M | $58.53M | $56.96M | $70.26M | $66.67M | $64.75M | $66.22M | $72.98M | $61.91M | $60.24M | $59.48M | $58.73M | $47.68M | $63.75M |
| Other Expenses | $4.96M | $5.57M | $-496.00K | $429.00K | $-682.00K | $-229.00K | $1.24M | $6.01M | $6.26M | $6.37M | $6.44M | $6.69M | $-177.00K | $-493.00K | $105.00K | $746.00K | $371.00K | $259.00K | $-10.00K | $-930.00K |
| Operating Expenses | $69.09M | $73.04M | $68.28M | $63.98M | $71.11M | $71.77M | $69.48M | $64.54M | $63.22M | $76.62M | $73.11M | $71.44M | $72.47M | $79.15M | $67.67M | $66.12M | $65.44M | $64.76M | $53.75M | $69.99M |
| Cost and Expenses | $198.35M | $199.21M | $195.10M | $194.84M | $195.91M | $198.07M | $194.12M | $196.65M | $188.34M | $204.89M | $190.04M | $189.51M | $191.88M | $197.67M | $177.84M | $166.82M | $165.34M | $164.52M | $149.28M | $177.32M |
| Interest Income | $- | $- | $- | $- | $16.57M | $17.61M | $17.72M | $18.98M | $17.92M | $16.98M | $- | $- | $- | $- | $- | $- | $- | $- | $24.00K | $22.00K |
| Interest Expense | $11.46M | $12.28M | $13.14M | $15.26M | $16.57M | $17.61M | $17.72M | $18.98M | $17.92M | $16.98M | $15.29M | $15.97M | $16.92M | $16.31M | $15.08M | $18.98M | $20.14M | $21.27M | $21.96M | $22.47M |
| Depreciation and Amortization | $4.96M | $5.57M | $8.12M | $7.84M | $7.65M | $5.67M | $8.79M | $9.48M | $9.84M | $9.74M | $9.88M | $10.16M | $9.73M | $9.62M | $9.29M | $9.26M | $7.61M | $7.55M | $7.47M | $6.24M |
| EBITDA | $98.48M | $89.51M | $80.17M | $90.00M | $93.80M | $97.24M | $91.99M | $-271.07M | $92.29M | $89.94M | $92.63M | $78.20M | $88.66M | $82.11M | $97.21M | $63.85M | $81.05M | $80.45M | $87.59M | $76.11M |
| EBITDA Ratio | 33.92% | 31.57% | 30.01% | 32.49% | 33.17% | 33.96% | 32.94% | -94.82% | 33.50% | 31.09% | 33.43% | 29.30% | 32.30% | 29.73% | 36.11% | 26.86% | 33.94% | 33.89% | 38.18% | 30.29% |
| Operating Income | $91.96M | $84.34M | $72.05M | $82.15M | $86.83M | $88.25M | $85.19M | $89.67M | $87.18M | $84.38M | $87.01M | $77.42M | $82.59M | $78.56M | $91.34M | $70.94M | $73.44M | $72.90M | $80.12M | $73.92M |
| Operating Income Ratio | 31.68% | 29.74% | 26.97% | 29.66% | 30.71% | 30.82% | 30.50% | 31.37% | 31.64% | 29.17% | 31.41% | 29.01% | 30.09% | 28.44% | 33.93% | 29.84% | 30.76% | 30.71% | 34.93% | 29.42% |
| Total Other Income Expenses Net | $-11.81M | $-12.68M | $-13.63M | $-14.83M | $-17.26M | $-17.84M | $-16.48M | $-18.52M | $-19.07M | $-17.79M | $-16.12M | $-16.46M | $-17.10M | $-18.93M | $-14.97M | $-30.56M | $-19.77M | $-21.01M | $-21.95M | $-23.38M |
| Income Before Tax | $80.15M | $71.66M | $58.41M | $67.32M | $69.58M | $70.42M | $68.71M | $-299.52M | $68.12M | $66.59M | $70.90M | $60.97M | $65.49M | $59.63M | $76.37M | $40.37M | $53.68M | $51.90M | $58.17M | $50.53M |
| Income Before Tax Ratio | 27.61% | 25.27% | 21.87% | 24.30% | 24.61% | 24.59% | 24.60% | -104.78% | 24.72% | 23.02% | 25.59% | 22.84% | 23.86% | 21.59% | 28.37% | 16.98% | 22.48% | 21.86% | 25.36% | 20.11% |
| Income Tax Expense | $19.12M | $17.29M | $9.35M | $17.86M | $16.53M | $16.86M | $15.44M | $-58.97M | $16.17M | $15.57M | $15.62M | $8.88M | $15.28M | $14.30M | $18.61M | $4.86M | $12.80M | $7.31M | $14.46M | $13.49M |
| Net Income | $61.03M | $54.38M | $49.07M | $49.46M | $53.05M | $53.56M | $53.28M | $-240.55M | $51.95M | $51.02M | $55.27M | $52.09M | $50.22M | $45.33M | $57.76M | $35.51M | $40.87M | $44.59M | $43.71M | $37.05M |
| Net Income Ratio | 21.02% | 19.18% | 18.37% | 17.86% | 18.76% | 18.71% | 19.07% | -84.15% | 18.86% | 17.64% | 19.95% | 19.51% | 18.30% | 16.41% | 21.46% | 14.94% | 17.12% | 18.78% | 19.05% | 14.75% |
| EPS | $1.23 | $1.10 | $0.98 | $0.99 | $1.07 | $1.08 | $1.07 | $-4.83 | $1.05 | $1.02 | $1.09 | $1.02 | $1.00 | $0.90 | $1.15 | $0.71 | $0.81 | $0.89 | $0.87 | $0.74 |
| EPS Diluted | $1.22 | $1.09 | $0.98 | $0.98 | $1.06 | $1.07 | $1.06 | $-4.83 | $1.04 | $1.02 | $1.09 | $1.02 | $0.99 | $0.89 | $1.14 | $0.70 | $0.81 | $0.88 | $0.86 | $0.73 |
| Weighted Average Shares Outstanding | 49.60M | 49.65M | 49.89M | 49.83M | 49.74M | 49.69M | 49.77M | 49.80M | 49.69M | 49.80M | 50.26M | 50.36M | 50.30M | 50.23M | 50.14M | 50.03M | 50.21M | 50.33M | 50.26M | 50.37M |
| Weighted Average Shares Outstanding Diluted | 49.99M | 50.00M | 50.27M | 50.31M | 50.12M | 50.08M | 50.20M | 49.80M | 50.19M | 50.27M | 50.73M | 50.97M | 50.94M | 50.79M | 50.67M | 50.51M | 50.56M | 50.66M | 50.81M | 50.88M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $46.47M | $58.49M | $27.18M | $32.30M | $94.76M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $46.47M | $58.49M | $27.18M | $32.30M | $94.76M |
| Net Receivables | $176.78M | $167.02M | $139.33M | $114.67M | $150.52M |
| Inventory | $138.72M | $162.12M | $120.34M | $114.96M | $116.03M |
| Other Current Assets | $13.08M | $4.12M | $12.82M | $15.81M | $8.70M |
| Total Current Assets | $375.04M | $391.74M | $293.27M | $269.83M | $365.65M |
| Property Plant Equipment Net | $89.33M | $89.53M | $98.53M | $102.77M | $90.72M |
| Goodwill | $527.73M | $527.55M | $578.98M | $578.08M | $575.18M |
| Intangible Assets | $2.32B | $2.34B | $2.70B | $2.48B | $2.48B |
| Goodwill and Intangible Assets | $2.85B | $2.87B | $3.28B | $3.05B | $3.05B |
| Long Term Investments | $- | $- | $-444.92M | $-434.05M | $-407.81M |
| Tax Assets | $- | $380.43M | $444.92M | $434.05M | $407.81M |
| Other Non-Current Assets | $5.72M | $-377.43M | $3.27M | $2.86M | $2.96M |
| Total Non-Current Assets | $2.94B | $2.96B | $3.38B | $3.16B | $3.15B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $3.32B | $3.35B | $3.67B | $3.43B | $3.51B |
| Account Payables | $38.98M | $62.74M | $55.76M | $45.98M | $62.38M |
| Short Term Debt | $6.15M | $19.52M | $18.22M | $16.89M | $13.66M |
| Tax Payables | $2.57M | $10.64M | $2.67M | $4.02M | $5.13M |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $69.35M | $67.81M | $66.76M | $55.25M | $68.72M |
| Total Current Liabilities | $117.05M | $160.72M | $143.42M | $122.14M | $149.88M |
| Long Term Debt | $1.13B | $1.36B | $1.50B | $1.51B | $1.76B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $403.60M | $380.43M | $444.92M | $434.05M | $407.81M |
| Other Non-Current Liabilities | $9.19M | $8.16M | $7.48M | $8.61M | $25.44M |
| Total Non-Current Liabilities | $1.55B | $1.75B | $1.95B | $1.95B | $2.19B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.66B | $1.91B | $2.09B | $2.07B | $2.34B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $555.00K | $548.00K | $544.00K | $540.00K | $538.00K |
| Retained Earnings | $1.34B | $1.13B | $1.21B | $1.01B | $844.10M |
| Accumulated Other Comprehensive Income Loss | $-34.49M | $-31.56M | $-19.03M | $-19.80M | $-44.16M |
| Other Total Stockholders Equity | $347.83M | $346.24M | $381.94M | $368.78M | $370.49M |
| Total Stockholders Equity | $1.66B | $1.45B | $1.58B | $1.36B | $1.17B |
| Total Equity | $1.66B | $1.45B | $1.58B | $1.36B | $1.17B |
| Total Liabilities and Stockholders Equity | $3.32B | $3.35B | $3.67B | $3.43B | $3.51B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.32B | $3.35B | $3.67B | $3.43B | $3.51B |
| Total Investments | $-403.60M | $- | $-444.92M | $-434.05M | $-407.81M |
| Total Debt | $1.14B | $1.37B | $1.51B | $1.51B | $1.77B |
| Net Debt | $1.09B | $1.31B | $1.48B | $1.48B | $1.67B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $50.87M | $51.54M | $34.26M | $46.47M | $63.62M | $60.07M | $54.58M | $58.49M | $86.36M | $42.44M | $35.87M | $27.18M | $21.02M | $42.82M | $163.62M | $32.30M | $62.10M | $26.60M | $57.94M | $94.76M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $50.87M | $51.54M | $34.26M | $46.47M | $63.62M | $60.07M | $54.58M | $58.49M | $86.36M | $42.44M | $35.87M | $27.18M | $21.02M | $42.82M | $163.62M | $32.30M | $62.10M | $26.60M | $57.94M | $94.76M |
| Net Receivables | $167.27M | $163.55M | $171.69M | $176.78M | $174.29M | $158.46M | $157.95M | $167.02M | $157.08M | $145.99M | $145.45M | $139.33M | $134.26M | $146.55M | $130.35M | $114.67M | $116.00M | $122.21M | $112.32M | $150.52M |
| Inventory | $151.52M | $156.22M | $152.04M | $138.72M | $148.64M | $161.28M | $169.85M | $162.12M | $158.52M | $140.50M | $133.77M | $120.34M | $106.27M | $107.92M | $105.55M | $114.96M | $117.01M | $114.03M | $116.81M | $116.03M |
| Other Current Assets | $7.50M | $9.40M | $10.75M | $13.08M | $7.25M | $8.39M | $9.38M | $4.12M | $6.89M | $15.43M | $19.05M | $12.82M | $27.42M | $15.04M | $18.02M | $15.81M | $12.19M | $14.03M | $16.98M | $8.70M |
| Total Current Assets | $377.16M | $380.71M | $368.74M | $375.04M | $393.79M | $388.20M | $391.76M | $391.74M | $408.85M | $336.65M | $324.62M | $293.27M | $275.27M | $304.81M | $408.52M | $269.83M | $301.21M | $269.85M | $295.56M | $365.65M |
| Property Plant Equipment Net | $108.12M | $83.68M | $86.28M | $89.33M | $83.26M | $85.70M | $86.96M | $89.53M | $90.84M | $92.78M | $95.47M | $98.53M | $98.70M | $99.73M | $100.51M | $102.77M | $103.11M | $102.27M | $91.50M | $90.72M |
| Goodwill | $527.22M | $529.23M | $528.44M | $527.73M | $527.88M | $526.86M | $527.46M | $527.55M | $576.60M | $575.57M | $576.79M | $578.98M | $578.93M | $578.80M | $577.84M | $578.08M | $579.56M | $577.92M | $577.13M | $575.18M |
| Intangible Assets | $2.31B | $2.32B | $2.32B | $2.32B | $2.33B | $2.33B | $2.34B | $2.34B | $2.67B | $2.67B | $2.68B | $2.70B | $2.70B | $2.69B | $2.47B | $2.48B | $2.48B | $2.48B | $2.48B | $2.48B |
| Goodwill and Intangible Assets | $2.84B | $2.85B | $2.85B | $2.85B | $2.86B | $2.86B | $2.86B | $2.87B | $3.25B | $3.25B | $3.26B | $3.28B | $3.28B | $3.27B | $3.05B | $3.05B | $3.06B | $3.06B | $3.06B | $3.05B |
| Long Term Investments | $- | $- | $-409.08M | $-403.60M | $-397.15M | $-388.48M | $-383.95M | $- | $- | $- | $- | $-444.92M | $-444.77M | $-440.27M | $-439.43M | $-39.78M | $-424.36M | $-416.38M | $-417.23M | $- |
| Tax Assets | $- | $- | $409.08M | $38.49M | $397.15M | $388.48M | $383.95M | $380.43M | $455.83M | $443.27M | $442.54M | $444.92M | $444.77M | $440.27M | $439.43M | $39.78M | $424.36M | $416.38M | $417.23M | $- |
| Other Non-Current Assets | $6.34M | $6.73M | $6.23M | $409.32M | $6.30M | $3.86M | $3.27M | $-377.43M | $-452.67M | $-440.69M | $-439.79M | $3.27M | $2.89M | $2.56M | $2.52M | $2.86M | $3.16M | $3.03M | $2.90M | $2.96M |
| Total Non-Current Assets | $2.95B | $2.94B | $2.94B | $2.98B | $2.95B | $2.94B | $2.95B | $2.96B | $3.34B | $3.34B | $3.36B | $3.38B | $3.38B | $3.37B | $3.15B | $3.16B | $3.17B | $3.16B | $3.15B | $3.15B |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.33B | $3.32B | $3.31B | $3.36B | $3.34B | $3.33B | $3.35B | $3.35B | $3.75B | $3.68B | $3.68B | $3.67B | $3.66B | $3.68B | $3.56B | $3.43B | $3.47B | $3.43B | $3.45B | $3.51B |
| Account Payables | $19.51M | $31.17M | $39.56M | $38.98M | $39.34M | $44.38M | $57.86M | $62.74M | $64.25M | $56.20M | $58.11M | $55.76M | $40.10M | $38.05M | $30.96M | $45.98M | $29.11M | $55.42M | $21.12M | $62.38M |
| Short Term Debt | $6.92M | $2.65M | $8.90M | $12.30M | $15.68M | $19.22M | $18.91M | $19.52M | $19.34M | $18.88M | $18.64M | $18.22M | $17.84M | $23.42M | $17.16M | $10.81M | $8.39M | $8.98M | $13.36M | $8.74M |
| Tax Payables | $436.00K | $104.00K | $189.00K | $2.57M | $5.95M | $8.16M | $9.76M | $10.64M | $6.97M | $12.46M | $13.83M | $2.67M | $497.00K | $2.53M | $9.46M | $4.02M | $522.00K | $3.83M | $11.23M | $5.13M |
| Deferred Revenue | $- | $- | $189.00K | $2.57M | $- | $- | $- | $- | $- | $- | $442.54M | $- | $- | $2.53M | $9.46M | $434.05M | $522.00K | $3.83M | $11.23M | $407.81M |
| Other Current Liabilities | $75.69M | $72.98M | $65.47M | $63.20M | $66.47M | $57.95M | $60.74M | $67.81M | $69.61M | $64.78M | $64.77M | $66.76M | $76.69M | $84.94M | $67.46M | $61.33M | $88.14M | $67.88M | $86.22M | $73.64M |
| Total Current Liabilities | $102.55M | $106.91M | $114.11M | $117.05M | $127.44M | $129.70M | $147.27M | $160.72M | $160.18M | $152.31M | $155.35M | $143.42M | $135.13M | $148.94M | $125.05M | $122.14M | $126.16M | $136.12M | $131.93M | $149.88M |
| Long Term Debt | $56.49M | $1.06B | $1.10B | $1.13B | $1.21B | $1.27B | $1.33B | $1.36B | $1.44B | $1.45B | $1.49B | $1.50B | $1.55B | $1.62B | $1.57B | $1.51B | $1.58B | $1.58B | $1.65B | $1.76B |
| Deferred Revenue Non-Current | $- | $- | $7.20M | $46.19M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $413.28M | $- | $409.08M | $442.08M | $397.15M | $388.48M | $383.95M | $380.43M | $455.83M | $443.27M | $442.54M | $444.92M | $444.77M | $440.27M | $439.43M | $434.05M | $424.36M | $416.38M | $417.23M | $407.81M |
| Other Non-Current Liabilities | $968.75M | $419.99M | $5.14M | $412.78M | $8.92M | $8.90M | $8.18M | $8.16M | $8.87M | $8.88M | $8.92M | $7.48M | $8.43M | $8.49M | $8.55M | $8.61M | $17.84M | $24.61M | $25.26M | $25.44M |
| Total Non-Current Liabilities | $1.44B | $1.48B | $1.51B | $1.58B | $1.61B | $1.67B | $1.72B | $1.75B | $1.90B | $1.91B | $1.94B | $1.95B | $2.01B | $2.07B | $2.02B | $1.95B | $2.02B | $2.02B | $2.09B | $2.19B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.54B | $1.59B | $1.63B | $1.70B | $1.74B | $1.80B | $1.87B | $1.91B | $2.06B | $2.06B | $2.10B | $2.09B | $2.14B | $2.21B | $2.14B | $2.07B | $2.15B | $2.16B | $2.22B | $2.34B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $161.00K |
| Common Stock | $- | $- | $557.00K | $555.00K | $553.00K | $552.00K | $552.00K | $548.00K | $548.00K | $547.00K | $547.00K | $544.00K | $543.00K | $542.00K | $542.00K | $540.00K | $539.00K | $539.00K | $539.00K | $538.00K |
| Retained Earnings | $1.51B | $1.44B | $1.39B | $1.34B | $1.29B | $1.24B | $1.19B | $1.13B | $1.37B | $1.32B | $1.27B | $1.21B | $1.16B | $1.11B | $1.07B | $1.01B | $973.27M | $932.40M | $887.81M | $844.10M |
| Accumulated Other Comprehensive Income Loss | $-40.16M | $-26.54M | $-31.34M | $-34.49M | $-28.53M | $-35.99M | $-32.21M | $-31.56M | $-29.49M | $-36.46M | $-29.34M | $-19.03M | $-23.21M | $-24.42M | $-20.77M | $-19.80M | $-17.23M | $-28.61M | $-33.26M | $-44.16M |
| Other Total Stockholders Equity | $322.92M | $313.65M | $321.28M | $347.83M | $336.81M | $332.71M | $326.82M | $346.24M | $343.39M | $335.29M | $344.10M | $381.94M | $378.91M | $373.66M | $369.94M | $368.78M | $366.64M | $373.89M | $371.93M | $370.49M |
| Total Stockholders Equity | $1.79B | $1.73B | $1.68B | $1.66B | $1.60B | $1.54B | $1.48B | $1.45B | $1.69B | $1.62B | $1.58B | $1.58B | $1.52B | $1.46B | $1.42B | $1.36B | $1.32B | $1.28B | $1.23B | $1.17B |
| Total Equity | $1.79B | $1.73B | $1.68B | $1.66B | $1.60B | $1.54B | $1.48B | $1.45B | $1.69B | $1.62B | $1.58B | $1.58B | $1.52B | $1.46B | $1.42B | $1.36B | $1.32B | $1.28B | $1.23B | $1.17B |
| Total Liabilities and Stockholders Equity | $3.33B | $3.32B | $3.31B | $3.36B | $3.34B | $3.33B | $3.35B | $3.35B | $3.75B | $3.68B | $3.68B | $3.67B | $3.66B | $3.68B | $3.56B | $3.43B | $3.47B | $3.43B | $3.45B | $3.51B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.33B | $3.32B | $3.31B | $3.36B | $3.34B | $3.33B | $3.35B | $3.35B | $3.75B | $3.68B | $3.68B | $3.67B | $3.66B | $3.68B | $3.56B | $3.43B | $3.47B | $3.43B | $3.45B | $3.51B |
| Total Investments | $- | $- | $-409.08M | $-403.60M | $-397.15M | $-388.48M | $-383.95M | $- | $- | $- | $- | $-444.92M | $-444.77M | $-440.27M | $-439.43M | $-39.78M | $-424.36M | $-416.38M | $-417.23M | $- |
| Total Debt | $1.03B | $1.06B | $1.10B | $1.14B | $1.21B | $1.28B | $1.34B | $1.37B | $1.45B | $1.46B | $1.50B | $1.51B | $1.56B | $1.63B | $1.58B | $1.51B | $1.59B | $1.59B | $1.66B | $1.77B |
| Net Debt | $976.26M | $1.01B | $1.07B | $1.09B | $1.15B | $1.22B | $1.28B | $1.31B | $1.36B | $1.42B | $1.46B | $1.48B | $1.54B | $1.59B | $1.41B | $1.48B | $1.52B | $1.56B | $1.60B | $1.67B |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $209.34M | $-82.31M | $205.38M | $164.68M | $142.28M |
| Depreciation and Amortization | $30.68M | $32.62M | $32.09M | $30.16M | $29.00M |
| Deferred Income Tax | $23.07M | $-60.77M | $9.98M | $18.63M | $13.85M |
| Stock Based Compensation | $14.01M | $12.40M | $9.04M | $8.54M | $7.64M |
| Change in Working Capital | $-39.83M | $-53.85M | $-10.95M | $-5.60M | $8.80M |
| Accounts Receivables | $-6.32M | $-24.93M | $-24.65M | $36.87M | $-2.85M |
| Inventory | $24.44M | $-42.23M | $663.00K | $2.97M | $2.93M |
| Accounts Payables | $-24.97M | $7.26M | $9.15M | $-17.34M | $6.21M |
| Other Working Capital | $-32.98M | $6.04M | $3.89M | $-28.10M | $2.51M |
| Other Non Cash Items | $11.66M | $381.61M | $14.38M | $19.19M | $15.55M |
| Net Cash Provided by Operating Activities | $248.93M | $229.72M | $259.92M | $235.61M | $217.12M |
| Investments in Property Plant and Equipment | $-9.55M | $-7.78M | $-9.64M | $-22.24M | $-17.32M |
| Acquisitions Net | $-10.56M | $-3.80M | $-247.05M | $- | $-2.76M |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-3.80M | $177.00K | $- | $3.51M |
| Net Cash Used for Investing Activities | $-20.11M | $-11.58M | $-256.51M | $-22.24M | $-16.57M |
| Debt Repayment | $-227.83M | $-137.75M | $-11.69M | $-269.16M | $-75.06M |
| Common Stock Issued | $- | $- | $7.04M | $- | $- |
| Common Stock Repurchased | $-25.00M | $-50.00M | $-2.92M | $-11.87M | $-56.72M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $11.81M | $1.91M | $7.04M | $1.61M | $350.00K |
| Net Cash Used Provided by Financing Activities | $-241.01M | $-185.85M | $-7.57M | $-279.42M | $-131.43M |
| Effect of Forex Changes on Cash | $180.00K | $-982.00K | $-959.00K | $3.60M | $-1.89M |
| Net Change in Cash | $-12.02M | $31.30M | $-5.12M | $-62.46M | $67.23M |
| Cash at End of Period | $46.47M | $58.49M | $27.18M | $32.30M | $94.76M |
| Cash at Beginning of Period | $58.49M | $27.18M | $32.30M | $94.76M | $27.53M |
| Operating Cash Flow | $248.93M | $229.72M | $259.92M | $235.61M | $217.12M |
| Capital Expenditure | $-9.55M | $-7.78M | $-9.64M | $-22.24M | $-17.32M |
| Free Cash Flow | $239.38M | $221.93M | $250.28M | $213.36M | $199.80M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $61.03M | $54.38M | $49.07M | $49.46M | $53.05M | $53.56M | $53.28M | $-240.55M | $51.95M | $51.02M | $55.27M | $52.09M | $50.22M | $45.33M | $57.76M | $35.51M | $40.87M | $44.59M | $43.71M | $37.05M |
| Depreciation and Amortization | $6.87M | $7.93M | $8.12M | $7.84M | $7.65M | $7.64M | $7.54M | $7.86M | $8.13M | $8.25M | $8.38M | $8.48M | $8.05M | $7.96M | $7.59M | $7.54M | $7.61M | $7.55M | $7.47M | $7.33M |
| Deferred Income Tax | $- | $-612.00K | $612.00K | $8.18M | $5.17M | $5.45M | $4.27M | $-74.79M | $9.81M | $3.00M | $1.21M | $-1.32M | $3.66M | $1.76M | $5.88M | $10.66M | $4.31M | $-2.49M | $6.15M | $6.47M |
| Stock Based Compensation | $2.87M | $2.13M | $3.42M | $3.73M | $2.45M | $3.69M | $4.15M | $2.65M | $2.43M | $3.47M | $3.86M | $1.71M | $2.23M | $3.22M | $1.88M | $2.60M | $1.59M | $2.89M | $1.46M | $1.96M |
| Change in Working Capital | $-10.91M | $-622.00K | $-8.62M | $-5.51M | $18.00K | $-10.96M | $-23.38M | $-9.87M | $-19.99M | $-10.74M | $-13.26M | $-2.17M | $-970.00K | $-1.53M | $-6.27M | $-6.33M | $-8.49M | $-3.82M | $13.05M | $-976.00K |
| Accounts Receivables | $-6.32M | $8.82M | $6.37M | $695.00K | $-11.43M | $-1.22M | $5.63M | $-7.85M | $-8.80M | $-1.20M | $-7.08M | $-2.81M | $12.47M | $-18.44M | $-15.88M | $147.00K | $7.37M | $-10.38M | $39.73M | $-7.47M |
| Inventory | $3.09M | $-3.42M | $-13.05M | $10.65M | $13.57M | $7.93M | $-7.71M | $-3.64M | $-16.78M | $-7.39M | $-14.41M | $-13.99M | $1.67M | $3.59M | $9.38M | $1.70M | $-1.94M | $3.16M | $51.00K | $3.75M |
| Accounts Payables | $-11.26M | $-8.19M | $591.00K | $-1.01M | $-5.14M | $-13.22M | $-5.60M | $-1.63M | $7.88M | $-1.53M | $2.54M | $15.23M | $2.20M | $7.28M | $-15.55M | $18.45M | $-26.61M | $23.20M | $-32.39M | $12.30M |
| Other Working Capital | $3.57M | $2.17M | $-2.53M | $-15.85M | $3.03M | $-4.46M | $-15.70M | $3.25M | $-2.28M | $-620.00K | $5.69M | $-607.00K | $-17.31M | $6.04M | $15.77M | $-26.63M | $12.69M | $-19.81M | $5.65M | $-9.55M |
| Other Non Cash Items | $5.24M | $6.59M | $27.93M | $12.29M | $3.14M | $3.08M | $2.23M | $373.68M | $2.60M | $2.54M | $2.78M | $4.33M | $3.11M | $4.46M | $2.48M | $9.11M | $3.33M | $3.42M | $3.32M | $4.29M |
| Net Cash Provided by Operating Activities | $65.09M | $69.80M | $54.78M | $66.91M | $71.47M | $62.46M | $48.09M | $58.99M | $54.94M | $57.54M | $58.25M | $63.13M | $66.30M | $61.19M | $69.31M | $59.09M | $49.23M | $52.14M | $75.15M | $56.13M |
| Investments in Property Plant and Equipment | $-1.57M | $-2.03M | $-1.15M | $-3.14M | $-2.00M | $-2.93M | $-1.48M | $-2.56M | $-1.80M | $-2.38M | $-1.05M | $-3.16M | $-2.23M | $-2.75M | $-1.50M | $-4.90M | $-5.73M | $-9.07M | $-2.55M | $-8.27M |
| Acquisitions Net | $- | $- | $- | $-10.56M | $- | $- | $- | $-3.80M | $- | $- | $- | $-132.00K | $-18.00M | $-228.91M | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-8.25M | $- | $-978.00K | $-11.86M | $-2.50M | $- | $3.80M | $-3.80M | $- | $- | $- | $-18.13M | $- | $-228.91M | $177.00K | $- | $- | $- | $- | $-2.76M |
| Net Cash Used for Investing Activities | $-9.82M | $-2.03M | $-2.13M | $-15.00M | $-4.50M | $-2.93M | $2.32M | $-6.36M | $-1.80M | $-2.38M | $-1.05M | $-3.29M | $-20.23M | $-231.67M | $-1.32M | $-4.90M | $-5.73M | $-9.07M | $-2.55M | $-8.27M |
| Debt Repayment | $-60.21M | $-40.97M | $-35.72M | $-75.72M | $-65.71M | $-55.70M | $-30.70M | $-80.69M | $-15.69M | $-35.68M | $-5.69M | $-55.44M | $-70.65M | $56.14M | $64.36M | $-83.24M | $-206.00K | $-74.38M | $-111.34M | $27.78M |
| Common Stock Issued | $- | $- | $- | $7.27M | $1.64M | $2.15M | $- | $7.37M | $5.68M | $- | $- | $1.32M | $5.72M | $503.00K | $2.20M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-2.40M | $-11.82M | $-25.98M | $- | $- | $- | $-25.00M | $- | $-16.00K | $-12.27M | $-37.73M | $- | $- | $- | $-2.92M | $-1.99M | $-8.88M | $-997.00K | $-1.24M | $-6.75M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $8.75M | $1.59M | $-3.83M | $7.27M | $-769.00K | $2.15M | $1.52M | $199.00K | $5.67M | $- | $-3.96M | $1.32M | $- | $-5.61M | $2.20M | $1.53M | $39.00K | $69.00K | $-26.00K | $-474.00K |
| Net Cash Used Provided by Financing Activities | $-53.87M | $-51.20M | $-65.52M | $-68.44M | $-64.84M | $-53.55M | $-54.18M | $-80.50M | $-10.02M | $-47.96M | $-47.37M | $-54.12M | $-67.64M | $50.53M | $63.65M | $-83.71M | $-9.04M | $-75.30M | $-111.36M | $20.56M |
| Effect of Forex Changes on Cash | $-2.08M | $711.00K | $663.00K | $-605.00K | $1.42M | $-490.00K | $-140.00K | $-3.00K | $798.00K | $-635.00K | $-1.14M | $449.00K | $-230.00K | $-868.00K | $-310.00K | $-283.00K | $1.04M | $893.00K | $1.94M | $-2.25M |
| Net Change in Cash | $-666.00K | $17.28M | $-12.21M | $-17.15M | $3.55M | $5.49M | $-3.91M | $-27.87M | $43.92M | $6.57M | $8.68M | $6.17M | $-21.80M | $-120.81M | $131.32M | $-29.80M | $35.50M | $-31.34M | $-36.82M | $66.17M |
| Cash at End of Period | $50.87M | $51.54M | $34.26M | $46.47M | $63.62M | $60.07M | $54.58M | $58.49M | $86.36M | $42.44M | $35.87M | $27.18M | $21.02M | $42.82M | $163.62M | $32.30M | $62.10M | $26.60M | $57.94M | $94.76M |
| Cash at Beginning of Period | $51.54M | $34.26M | $46.47M | $63.62M | $60.07M | $54.58M | $58.49M | $86.36M | $42.44M | $35.87M | $27.18M | $21.02M | $42.82M | $163.62M | $32.30M | $62.10M | $26.60M | $57.94M | $94.76M | $28.59M |
| Operating Cash Flow | $65.09M | $69.80M | $54.78M | $66.91M | $71.47M | $62.46M | $48.09M | $58.99M | $54.94M | $57.54M | $58.25M | $63.13M | $66.30M | $61.19M | $69.31M | $59.09M | $49.23M | $52.14M | $75.15M | $56.13M |
| Capital Expenditure | $-1.57M | $-2.03M | $-1.15M | $-3.14M | $-2.00M | $-2.93M | $-1.48M | $-2.56M | $-1.80M | $-2.38M | $-1.05M | $-3.16M | $-2.23M | $-2.75M | $-1.50M | $-4.90M | $-5.73M | $-9.07M | $-2.55M | $-8.27M |
| Free Cash Flow | $63.52M | $67.77M | $53.62M | $63.76M | $69.48M | $59.53M | $46.61M | $56.43M | $53.14M | $55.16M | $57.20M | $59.97M | $64.07M | $58.44M | $67.81M | $54.19M | $43.50M | $43.07M | $72.60M | $47.86M |
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
$81.23
Stock Price
$4.02B
Market Cap
570
Employees
Tarrytown, NY
Location
Revenue (FY 2024)
$1.13B
-0.2% YoY
Net Income (FY 2024)
$209.34M
354.3% YoY
EPS (FY 2024)
$4.17
352.7% YoY
Free Cash Flow (FY 2024)
$239.38M
7.9% YoY
Profitability
Gross Margin
55.5%
Net Margin
18.6%
ROE
12.6%
ROA
6.3%
Valuation
P/E Ratio
17.04
P/S Ratio
3.17
EV/EBITDA
12.46
Market Cap
$4.02B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$248.93M
8.4% YoY
Free Cash Flow
$239.38M
7.9% YoY
Balance Sheet Summary
Total Assets
$3.32B
-1.1% YoY
Total Debt
$1.14B
16.6% YoY
Shareholder Equity
$1.66B
14.7% YoY
Dividend Overview
$0.48
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2018-09-27 | $0.48 | September 27, 18 |
| 2013-12-27 | $0.31 | December 27, 13 |
Prestige Consumer Healthcare Dividends
Explore Prestige Consumer Healthcare's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
26.07x
Prestige Consumer Healthcare Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.475 | $0.475 | September 27, 2018 | October 15, 2018 | ||
| $0.3125 | $0.3125 | December 27, 2013 |
Prestige Consumer Healthcare News
Read the latest news about Prestige Consumer Healthcare, including recent articles, headlines, and updates.
Premium Brands Holdings Corporation to Release First Quarter 2025 Results
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2025) - Premium Brands Holdings Corporation (TSX: PBH) (the "Company"), a leading producer, marketer and distributor of branded specialty food products, will release its first quarter 2025 results on Wednesday, May 7, 2025. Pre-recorded Management Remarks, Press Release and Investor Presentation Please note that management's pre-recorded remarks, a press release including financial statements and segment information and an investor presentation will be available on the morning of Wednesday, May 7, 2025 at 4:00 a.m.
Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results
TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
Premium Brands Holdings Corporation Announces $150 Million Financing of Convertible Unsecured Subordinated Debentures
NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Premium Brands Holdings Corporation (“Premium Brands” or the “Company”) (TSX: PBH), a leading producer, marketer and distributor of branded specialty food products, is pleased to announce it has entered into an agreement with a syndicate of underwriters co-led by CIBC Capital Markets, National Bank Financial, BMO Capital Markets and Scotiabank (collectively, the “Underwriters”), pursuant to which the Company will issue on a “bought-deal” basis, subject to regulatory approval, $150,000,000 aggregate principal amount of convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Offering”). The Company has also granted the Underwriters an over-allotment option to purchase up to an additional $22,500,000 aggregate principal amount of Debentures, on the same terms, exercisable in whole or in part at any time for a period of up to 30 days following closing of the Offering, to cover over-allotments, if any.
Prestige Consumer Healthcare Inc. (PBH) Q3 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q3 2025 Results Conference Call February 6, 2025 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & Chief Executive Officer Christine Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer & Company Susan Anderson - Canaccord Genuity Keith Devas - Jefferies David Shakno - William Blair Linda Bolton Weiser - D. A. Davidson Anthony Lebiedzinski - Sidoti & Company Operator Thank you for standing by, and welcome to Prestige Consumer Healthcare's Third Quarter 2025 Earnings Conference Call.
Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook
TARRYTOWN, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2024.
PBH vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Premium Brands Holdings: Serving Up Protein On Both Sides Of The Border
Premium Brands Holdings has expanded from Western Canada to the US, focusing on specialty foods and wholesale distribution through acquisitions. PBH aims for $10B annual revenue by 2027, leveraging a portfolio mix of proteins, baked goods, and distribution, with 70% sales from foodservice and retail chains. The macro environment suggests lower interest rates, but inflation and wage increases could impact PBH's middle and low-income customer base.
Prestige Consumer Healthcare Inc (PBH) Q2 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc (NYSE:PBH ) Q2 2025 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & Chief Executive Officer Chris Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer Susan Anderson - Canaccord Anthony Lebiedzinski - Sidoti & Co. Operator Good day, ladies and gentlemen, and welcome to Prestige Consumer Healthcare's Second Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.
What Makes Prestige Consumer Healthcare (PBH) a Good Fit for 'Trend Investing'
Prestige Consumer Healthcare (PBH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PBH.